https://socictopen.socict.org/files/original/7846b2203c33eb16bf6facdee94bc528.pdf 260e2c449fca724192a915a7c7918de1 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. Creator An entity primarily responsible for making the resource Beth-Ann Coller, Samantha Bruno, Jayanthi Wolf, Michael Eichberg, Risat Jannat, Sharon Rudo, Susan VanRheenen Description An account of the resource The world is experiencing an unprecedented global pandemic of coronavirus disease 2019 (COVID-19) caused by a novel coronavirus, Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-CoV-2). Development of new vaccines and therapeutics are important to achieve long-term prevention and control of the virus. Experience gained in the development of vaccines for Ebola virus disease provide important lessons in the regulatory, clinical, and manufacturing process that can be applied to SARS-CoV-2 and other epidemic pathogens. This report outlines the main lessons learned by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD) during development of an Ebola Zaire vaccine (ERVEBO®) and looks ahead to critical lessons beyond vaccine development. It highlights focus areas for public-private partnership and regulatory harmonization that can be directly applied to current vaccine development efforts for SARS-CoV-2, while drawing attention to the need for parallel consideration of issues beyond development that are equally important to achieve global preparedness and response goals. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource Drug Development, Drug Regulation Identifier An unambiguous reference to the resource within a given context DOI: 10.1038/s41541-020-0204-7 Source A related resource from which the described resource is derived npj Vaccines Publisher An entity responsible for making the resource available Nature Publishing Group